Groowe Groowe / Newsroom / CELC
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CELC News

Celcuity Inc. Common Stock

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

globenewswire.com
CELC

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

globenewswire.com
CELC

CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials

globenewswire.com
PFE AZN UMBF CELC REGN

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

globenewswire.com
ONCY SLS CELC RNXT

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report USA - English India - English

prnewswire.com
CLVT LLY GSK JNJ SNY CELC CRBP BMY

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

globenewswire.com
CELC

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

newsfilecorp.com
CELC

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight

globenewswire.com
JAZZ PRE ABBV AMGN GILD BMY AZN INCY PFE CELC

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

globenewswire.com
CELC

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

globenewswire.com
CELC